Patents by Inventor Sunil Badve

Sunil Badve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10247732
    Abstract: Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p<0.0001). FOXA1 expression correlated positively with tumor size, extra-prostatic extension, angiolymphatic invasion, AR and metastasis but did not correlate with age, tumor stage, Gleason score, presence of PIN or multifocality, seminal vesicle or perineural invasion and status of surgical excision margins. Expression of GATA-3 was not seen in either normal epithelium or tumor. High FOXA1 expression is associated with development of metastatic prostate cancer.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: April 2, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Sunil Badve, Harikrishna Nakshatri
  • Patent number: 10233502
    Abstract: Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: March 19, 2019
    Assignees: Indiana University Research and Technology Corporation, Castle Biosciences, Incorporated
    Inventors: Sunil Badve, Yesim Gokmen-Polar, Patrick J. Loehrer, Robert Cook, Derek Maetzold
  • Patent number: 10174382
    Abstract: A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide/nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: January 8, 2019
    Assignees: University of Notre Dame, Indiana University Research and Technology Corporation
    Inventors: Steven Buechler, Sunil Badve, Yesim Gokmen-Polar
  • Publication number: 20170247766
    Abstract: A method for determining the likelihood of late ER? breast cancer disease relapse/recurrence is disclosed. Late ER+ breast cancer disease onset and/or recurrence is determined for a period of 5 to 20 years after an initial ER+ breast cancer disease onset in a patient. An ER+ breast cancer patient is assigned a risk score that is compared to a defined threshold value, and identifies the risk score as low risk or high risk for late breast cancer recurrence. A late ER+ breast cancer gene panel of 8 to 15 genes is provided. Subjects having a risk score greater than or equal to that of the threshold value are at a relatively high risk of recurrent disease, and are determined to benefit from aggressive therapeutic intervention, whereas subjects having a risk score less than the threshold value are at a relatively low risk of recurrent disease, and could forego treatment.
    Type: Application
    Filed: August 26, 2015
    Publication date: August 31, 2017
    Applicant: The University of Notre Dame du Lac
    Inventors: Steven Buechler, Sunil Badve
  • Publication number: 20170030916
    Abstract: Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p<0.0001). FOXA1 expression correlated positively with tumor size, extra-prostatic extension, angiolymphatic invasion, AR and metastasis but did not correlate with age, tumor stage, Gleason score, presence of PIN or multifocality, seminal vesicle or perineural invasion and status of surgical excision margins. Expression of GATA-3 was not seen in either normal epithelium or tumor. High FOXA1 expression is associated with development of metastatic prostate cancer.
    Type: Application
    Filed: September 21, 2016
    Publication date: February 2, 2017
    Inventors: Sunil Badve, Harikrishna Nakshatri
  • Publication number: 20160333413
    Abstract: A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide/nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.
    Type: Application
    Filed: May 13, 2015
    Publication date: November 17, 2016
    Applicants: University of Notre Dame, Indiana University School of Medicine
    Inventors: Steven Buechler, Sunil Badve, Yesim Gokmen-Polar
  • Publication number: 20140371081
    Abstract: Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers.
    Type: Application
    Filed: June 22, 2013
    Publication date: December 18, 2014
    Applicants: Indiana University Research and Technology Corporation, Castle Biosciences Incorporated
    Inventors: Sunil Badve, Yesim Gokmen-Polar, Patrick J. Loehrer, Robert Cook, Derek Maetzold
  • Publication number: 20130202717
    Abstract: Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p<0.0001). FOXA1 expression correlated positively with tumor size, extra-prostatic extension, angiolymphatic invasion, AR and metastasis but did not correlate with age, tumor stage, Gleason score, presence of PIN or multifocality, seminal vesicle or perineural invasion and status of surgical excision margins. Expression of GATA-3 was not seen in either normal epithelium or tumor. High FOXA1 expression is associated with development of metastatic prostate cancer.
    Type: Application
    Filed: June 1, 2011
    Publication date: August 8, 2013
    Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Sunil Badve, Harikrishna Nakshatri
  • Publication number: 20110269636
    Abstract: Aspects of the invention include methods for identifying patients with HER2+ cancers that are at a heightened risk for developing brain metastasis within three years of having been diagnosed with HER2+ cancer. Some embodiments are methods that include the steps of contacting at least a portion of the tumor tissue from patients with probes that interact with the products of a set of thirteen genes that are expressed in these patients at markedly higher levels than in similarly situated patients that are not a heightened risk for developing brain metastasis within this three year window. In some embodiments the tissue samples are assayed from the presence of RNA indicative of the expression of member of a set of 13 genes identified as being differentially expressed in patients with and without a heightened risk for developing brain metastasis.
    Type: Application
    Filed: November 29, 2010
    Publication date: November 3, 2011
    Applicant: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
    Inventors: Sunil Badve, Lang Li, George Sledge, Renata Duchnowaska, Jacek Jassem, Patricia Steeg
  • Publication number: 20100068717
    Abstract: Methods and compositions based on FOXA1 expression to predict long-term disease-free survival in patients with breast cancer are disclosed. In ER+ positive patients, expression of FOXA1 is useful in identifying a subgroup of patients with a better prognosis. FOXA1 expression correlates with luminal subtype breast cancer, and serves as a clinical marker for luminal subtype breast cancer. Expression of FOXA1 is useful as a prognostic marker for an effective response tumors and as a predictive marker for a greater likelihood of response to an anti-hormonal therapy. Prognostic ability of FOXA1 in low-risk breast cancers is useful in treatment decision making.
    Type: Application
    Filed: January 30, 2008
    Publication date: March 18, 2010
    Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Sunil Badve, Harikrishna Nakshatri